石药(01093.HK)TG103注射液联合二甲双胍治疗III期临床研究结果在EASD 2026公布

阿斯达克财经
Oct 02

石药集团(01093.HK) 公布,已于2026年第62届欧洲糖尿病研究协会年会(EASD2026)上,以简短口头讨论形式公布集团研发的胰高血糖素样肽-1(GLP-1)受体激动剂依达格鲁肽α注射液(TG103注射液)联合二甲双胍治疗中国成人2型糖尿病(T2DM)患者III期临床研究的阳性结果。该研究结果表明,TG103注射液在该人群中展现出良好的疗效和安全性。(sl/u)(港股报价延迟最少十五分钟...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10